Organisation paid for research Program year 2025 Source: CMS Open Payments

Ventura Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$284,330

126 payments

Through program year 2025, Ventura Clinical Trials is reported as receiving $284,330 in research payments, across 126 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,849 2
2024 Research $13,901 16
2023 Research $782 2
2022 Research $4,951 4
2021 Research $36,972 11
2020 Research $39,792 20
2019 Research $186,083 71

Breakdown

Who paid Research payments · program years 2019–2025
  1. CSL Behring $67,052 32 payments
  2. Genentech, Inc. $57,805 47 payments
  3. Merck Sharp & Dohme Corporation $31,479 9 payments
  4. Roche Products Limited $29,477 17 payments
  5. Horizon Therapeutics plc $29,442 2 payments
  6. Sanofi Pasteur Inc. $23,703 3 payments
  7. Bausch Health US, LLC $15,342 4 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $14,725 1 payment
  9. Eli Lilly and Company $6,138 4 payments
  10. Celgene Corporation $3,570 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II $52,803 15 payments
  2. A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol NO. MK-3222-011 $31,169 4 payments
  3. Ole $28,563 29 payments
  4. Crohn S Disease Program Cohort 1 Induction Cohort II Maintenance $25,177 11 payments
  5. H 030 014 Efficacy Immunogenicity and Safety Study of Clostridium difficile Toxoid Vaccine in Subjects at Risk for C difficile Infection $23,703 3 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $16,963 1 payment
  7. Open Label Maintenance Trial Global $16,020 14 payments
  8. A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Safety of Amiselimod (Mt-1303) in Subjects With Mild to Moderate Ulcerative Colitis (UC) $15,342 4 payments
  9. Adult Allogeneic Expanded Adipose-derived Stem Cells eASC for the Treatment of Complex Perianal Fistulas in Patients With Crohn's Disease ADMIRE-CD-II $14,725 1 payment
  10. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $14,249 17 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $14,725 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record